Home Cart 0 Sign in  
X

[ CAS No. 10269-01-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 10269-01-9
Chemical Structure| 10269-01-9
Chemical Structure| 10269-01-9
Structure of 10269-01-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 10269-01-9 ]

Related Doc. of [ 10269-01-9 ]

Alternatived Products of [ 10269-01-9 ]

Product Details of [ 10269-01-9 ]

CAS No. :10269-01-9 MDL No. :MFCD01026119
Formula : C7H8BrN Boiling Point : -
Linear Structure Formula :- InChI Key :SUYJXERPRICYRX-UHFFFAOYSA-N
M.W : 186.05 Pubchem ID :457587
Synonyms :

Calculated chemistry of [ 10269-01-9 ]

Physicochemical Properties

Num. heavy atoms : 9
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.14
Num. rotatable bonds : 1
Num. H-bond acceptors : 1.0
Num. H-bond donors : 1.0
Molar Refractivity : 41.82
TPSA : 26.02 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -10.11 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.98
Log Po/w (XLOGP3) : -3.77
Log Po/w (WLOGP) : 1.76
Log Po/w (MLOGP) : 2.3
Log Po/w (SILICOS-IT) : 2.13
Consensus Log Po/w : 0.88

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 3.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : 0.95
Solubility : 1670.0 mg/ml ; 9.0 mol/l
Class : Highly soluble
Log S (Ali) : 3.81
Solubility : 1210000.0 mg/ml ; 6520.0 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : -3.3
Solubility : 0.0941 mg/ml ; 0.000506 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.15

Safety of [ 10269-01-9 ]

Signal Word:Danger Class:8
Precautionary Statements:P273-P280-P305+P351+P338-P310 UN#:2735
Hazard Statements:H302-H314-H412 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 10269-01-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 10269-01-9 ]
  • Downstream synthetic route of [ 10269-01-9 ]

[ 10269-01-9 ] Synthesis Path-Upstream   1~19

  • 1
  • [ 10269-01-9 ]
  • [ 22726-00-7 ]
Reference: [1] Journal of Organic Chemistry, 2018, vol. 83, # 1, p. 260 - 266
  • 2
  • [ 183735-18-4 ]
  • [ 10269-01-9 ]
Reference: [1] Journal of the Chemical Society, 1932, p. 696,703
[2] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 14, p. 3720 - 3731
[3] MedChemComm, 2016, vol. 7, # 11, p. 2159 - 2166
  • 3
  • [ 6952-59-6 ]
  • [ 10269-01-9 ]
Reference: [1] Journal of the American Chemical Society, 2017, vol. 139, # 20, p. 7004 - 7011
[2] Journal of Organic Chemistry, 2009, vol. 74, # 5, p. 1964 - 1970
[3] ChemCatChem, 2014, vol. 6, # 2, p. 538 - 546
[4] Angewandte Chemie - International Edition, 2016, vol. 55, # 47, p. 14653 - 14657[5] Angew. Chem., 2016, vol. 128, # 47, p. 14873 - 14877,5
[6] Journal of medicinal chemistry, 1973, vol. 16, # 2, p. 101 - 106
[7] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 3, p. 819 - 823
  • 4
  • [ 51873-95-1 ]
  • [ 10269-01-9 ]
Reference: [1] Bulletin of the Korean Chemical Society, 2011, vol. 32, # 9, p. 3323 - 3326
[2] Bulletin of the Korean Chemical Society, 2011, vol. 32, # 9, p. 3448 - 3452
[3] Journal of Medicinal Chemistry, 1984, vol. 27, # 9, p. 1111 - 1118
[4] Journal of the Chinese Chemical Society, 2005, vol. 52, # 1, p. 109 - 112
  • 5
  • [ 122-51-0 ]
  • [ 591-19-5 ]
  • [ 10269-01-9 ]
Reference: [1] Patent: US2003/134885, 2003, A1,
[2] Patent: US2004/39038, 2004, A1,
  • 6
  • [ 6952-59-6 ]
  • [ 10269-01-9 ]
  • [ 215667-42-8 ]
Reference: [1] Synthetic Communications, 2002, vol. 32, # 8, p. 1265 - 1269
  • 7
  • [ 6952-59-6 ]
  • [ 10269-01-9 ]
Reference: [1] Chemical Communications, 2016, vol. 52, # 9, p. 1812 - 1815
  • 8
  • [ 51873-95-1 ]
  • [ 10269-01-9 ]
Reference: [1] Tetrahedron Letters, 2001, vol. 42, # 12, p. 2365 - 2368
[2] Tetrahedron Letters, 2001, vol. 42, # 12, p. 2365 - 2368
  • 9
  • [ 1104070-89-4 ]
  • [ 10269-01-9 ]
Reference: [1] Tetrahedron Letters, 2001, vol. 42, # 12, p. 2365 - 2368
[2] Tetrahedron Letters, 2001, vol. 42, # 12, p. 2365 - 2368
  • 10
  • [ 22726-00-7 ]
  • [ 10269-01-9 ]
Reference: [1] Archiv der Pharmazie (Weinheim, Germany), 1927, p. 390,400[2] Chem. Zentralbl., 1924, vol. 95, # II, p. 1404
[3] Journal of the American Chemical Society, 1959, vol. 81, p. 3725,3726
  • 11
  • [ 823-78-9 ]
  • [ 10269-01-9 ]
Reference: [1] Journal of the Chemical Society, 1932, p. 696,703
[2] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 14, p. 3720 - 3731
  • 12
  • [ 5071-96-5 ]
  • [ 10269-01-9 ]
Reference: [1] Chemistry - A European Journal, 2017, vol. 23, # 16, p. 3804 - 3809
  • 13
  • [ 100-46-9 ]
  • [ 10269-01-9 ]
Reference: [1] Chemistry - A European Journal, 2017, vol. 23, # 16, p. 3804 - 3809
  • 14
  • [ 24424-99-5 ]
  • [ 10269-01-9 ]
  • [ 67344-77-8 ]
YieldReaction ConditionsOperation in experiment
59%
Stage #1: With sodium hydroxide In tetrahydrofuran at 20℃; for 0.0833333 h;
Stage #2: for 0.5 h;
Stage #3: With lithium aluminium tetrahydride In ethyl acetate at 100℃; for 1 h; Microwave irradiation
Example 95
1-(3-Bromophenyl)-N-methylmethanamine
To bromobenzylamine (0.890 g, 4 mmol) in THF (9 mL) was added NaOH (4.20 mL, 1 N, 4.20 mmol) and the solution was stirred at room temperature for 5 mins, when BOC2O (0.975 mL, 4.20 mmol) was added.
This mixture was stirred for an additional 30 mins.
The reaction mixture was diluted with EtOAc (20 mL).
The organic layer was separated, washed with brine (5 mL), dried over Na2SO4, filtered and concentrated.
Lithium aluminum hydride (12.00 mL, 12.00 mmol) was added to the above crude product and heated in a microwave at about 100° C. for about 1 h.
The reaction mixture was diluted with Et2O (~50 mL) and quenched slowly with Na2SO4 (sat.).
The organic layer was separated, dried over, filtered, and concentrated to afford the title compound (0.472 g, 59percent). LC-MS m/z 200 (M+H)+.
Reference: [1] Patent: US2009/203677, 2009, A1, . Location in patent: Page/Page column 72; 73
  • 15
  • [ 10269-01-9 ]
  • [ 67344-77-8 ]
Reference: [1] Chemical Research in Toxicology, 1997, vol. 10, # 1, p. 19 - 26
[2] Patent: WO2009/100169, 2009, A1,
  • 16
  • [ 24424-99-5 ]
  • [ 10269-01-9 ]
  • [ 171663-13-1 ]
YieldReaction ConditionsOperation in experiment
100% With sodium hydroxide In tetrahydrofuran; water at 20℃; for 0.5 h; Sodium hydroxide (8.76 g, 219.0 mmol, 2.2 EQ.), di-tert-butyl dicarbonate (26.07 g, 119.45 MMOL, 1.2 EQ. ) AND WATER (100 ML) WERE ADDED TO A STIRRING SOLUTION OF
3-BROMOBENZYLAMINE (22.11 G, 99.55 MMOL, 1.0 EQ. ) IN TETRAHYDROFURAN (75 ML) OVER 30 minutes at room temperature. The mixture was extracted with dichloromethane and water twice. The organic phase was dried and concentrataed to give ter-butyl (3-BROMOBENZYL) -CARBAMATE (34.88G, 100percent). LCMS: CALCD 286; OBSD (M+23) 309).
100% With sodium hydrogencarbonate In tetrahydrofuran at 20℃; for 3 h; A 100-mL round-bottomed flask, equipped with magnetic stirring bar, was charged with THF (10 mL) and (3-bromophenyl) methanamine (1.86 g, 10 mmol) and sodium bicarbonate (1.68 g, 20 mmol), the di-tert-butyl dicarbonate (2.4 g, 11 mmol) was added. The resulted solution was stirred at room temperature for 3 h. The reaction mixture was filtered and the solvents are then removed under reduced pressure, the residue was pure enough for next step without further purification (2.86 g, yield: 100percent). m/z 286 (MH-H+).
99% at 20℃; for 15 h; To a solution of commercially available 3-bromo-benzylamine (938 mg) in dry dichloromethane (10 mL) was added added di-tert-butyl dicarbonate (1.10 g). The resulting clear solution was stirred at room temperature for 15 h and then concentrated to afford the title compound (1.42 g; 99percent). [(M-isobutene)H]+=230/232, [MNa]+=308/310.
92% With triethylamine In dichloromethane at 20℃; for 5.3 h; Cooling with ice Example 104
Production of tert-Butly N-[(3-bromophenyl)methyl]carbamate.
A methylene chloride (40 mL) solution of Boc2O(21.2 g, 97 mmol) was added dropwise to a methylene chloride (160 mL) solution of 3-bromobenzylamine (15.0 g, 81 mmol) and triethylamine (23 mL, 162 mmol) over 20 minutes, under ice-cooling, and the mixture was stirred at room temperature for 5 hours.
The reaction mixture was washed with water, and an organic layer was then dried over anhydrous sodium sulfate. n-Hexane was added to the residue obtained by distilling off the solvent under a reduced pressure, and the precipitated solid was collected by filtration, to give the captioned compound (19.8 g, 92percent).
Mp 41-42°C. 1H-NMR (DMSO-d6) δ: 1.39 (s, 9H), 4.12 (d, J=6.1 Hz, 2H), 7.23-7.28 (m, 2H), 7.40-7.42 (m, 3H).
80% With triethylamine In dichloromethane at 20℃; To a stirred solution of benzylamine derivative (1 equiv.) in dry DCM, triethylamine (1 .5 equiv.) and di-tert-butyl dicarbonate (1 -1 .2 equiv.) were added under azote atmosphere. The reaction mixture was stirred at room temperature until completion. Water was then added, the phases were separated and the aqueous phase was extracted once with DCM. The combined organic layers were washed with brine, dried over Na2S04, filtered and concentrated under vacuum. The crude mixture was then purified by flash column chromatography (0-10percent MeOH in DCM) to provide the expected compound. The following compounds are examples illustrating this procedure:; tert-butyl bomophenyl)methyllcarbamate was prepared from 3- bromobenzylamine (2 g, 10.75 mmol). Yield: 2.47g (80percent) of the title compound as a white powder

Reference: [1] Patent: WO2004/62661, 2004, A1, . Location in patent: Page/Page column 24
[2] Patent: WO2008/5457, 2008, A2, . Location in patent: Page/Page column 178
[3] Patent: US2006/173183, 2006, A1, . Location in patent: Page/Page column 83
[4] Journal of Medicinal Chemistry, 2018, vol. 61, # 16, p. 7358 - 7373
[5] Patent: EP2940003, 2015, A1, . Location in patent: Paragraph 0132
[6] Journal of Medicinal Chemistry, 2011, vol. 54, # 19, p. 6969 - 6983
[7] Journal of Medicinal Chemistry, 2017, vol. 60, # 11, p. 4636 - 4656
[8] Patent: WO2017/191297, 2017, A1, . Location in patent: Page/Page column 130
[9] Patent: WO2004/50637, 2004, A2, . Location in patent: Page 73-74
[10] Patent: US2009/203657, 2009, A1, . Location in patent: Page/Page column 69
[11] Patent: US2009/197871, 2009, A1, . Location in patent: Page/Page column 103
[12] Patent: WO2009/100169, 2009, A1, . Location in patent: Page/Page column 159
[13] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 14, p. 3720 - 3731
  • 17
  • [ 10269-01-9 ]
  • [ 171663-13-1 ]
Reference: [1] Patent: EP1380562, 2004, A1, . Location in patent: Page 108
  • 18
  • [ 110-86-1 ]
  • [ 10269-01-9 ]
  • [ 4422-32-6 ]
  • [ 4373-60-8 ]
Reference: [1] European Journal of Organic Chemistry, 2018, vol. 2018, # 22, p. 2831 - 2835
  • 19
  • [ 201230-82-2 ]
  • [ 10269-01-9 ]
  • [ 552330-86-6 ]
Reference: [1] Organic Letters, 2018, vol. 20, # 9, p. 2595 - 2598
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 10269-01-9 ]

Aryls

Chemical Structure| 3959-07-7

[ 3959-07-7 ]

4-Bromobenzylamine

Similarity: 0.97

Chemical Structure| 26177-44-6

[ 26177-44-6 ]

(4-Bromophenyl)methanamine hydrochloride

Similarity: 0.94

Chemical Structure| 67344-77-8

[ 67344-77-8 ]

1-(3-Bromophenyl)-N-methylmethanamine

Similarity: 0.92

Chemical Structure| 376646-62-7

[ 376646-62-7 ]

(4-Bromo-2-methylphenyl)methanamine

Similarity: 0.92

Chemical Structure| 1171381-49-9

[ 1171381-49-9 ]

(4-Bromo-2-methylphenyl)methanamine hydrochloride

Similarity: 0.89

Bromides

Chemical Structure| 3959-07-7

[ 3959-07-7 ]

4-Bromobenzylamine

Similarity: 0.97

Chemical Structure| 26177-44-6

[ 26177-44-6 ]

(4-Bromophenyl)methanamine hydrochloride

Similarity: 0.94

Chemical Structure| 67344-77-8

[ 67344-77-8 ]

1-(3-Bromophenyl)-N-methylmethanamine

Similarity: 0.92

Chemical Structure| 376646-62-7

[ 376646-62-7 ]

(4-Bromo-2-methylphenyl)methanamine

Similarity: 0.92

Chemical Structure| 1171381-49-9

[ 1171381-49-9 ]

(4-Bromo-2-methylphenyl)methanamine hydrochloride

Similarity: 0.89

Amines

Chemical Structure| 3959-07-7

[ 3959-07-7 ]

4-Bromobenzylamine

Similarity: 0.97

Chemical Structure| 26177-44-6

[ 26177-44-6 ]

(4-Bromophenyl)methanamine hydrochloride

Similarity: 0.94

Chemical Structure| 67344-77-8

[ 67344-77-8 ]

1-(3-Bromophenyl)-N-methylmethanamine

Similarity: 0.92

Chemical Structure| 376646-62-7

[ 376646-62-7 ]

(4-Bromo-2-methylphenyl)methanamine

Similarity: 0.92

Chemical Structure| 1171381-49-9

[ 1171381-49-9 ]

(4-Bromo-2-methylphenyl)methanamine hydrochloride

Similarity: 0.89